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SUMMARY: 1.—Histories of antibiotic resistance. 2.—A therapy with side effects. 3.—The 
impact of resistance. 4.—A «wholly mysterious phenomenon». 5.—A revival. 6.—Conclusions.
ABSTRACT: It was in the 1940s that antibiotic resistance arose as an object of study for clinical 
medicine. Somewhat earlier it had become an important analytical tool for bacterial geneticists. 
However, the concept of antibiotic resistance as an induced and inheritable trait of microbial 
species was introduced a generation earlier in the years preceding the First World War. The 
paper reconstructs the concept that was put forward by the German immunologist Paul Ehr-
lich in 1907. He came across the phenomenon when trying to develop chemotherapies for 
trypa n osomiasis, the best known of which is African sleeping sickness. However, resistance was 
studied by him for other than therapy-related purposes. It provided a productive laboratory 
model for the study of cell functions. Induced resistance to chemicals facilitated the develo-
pment of ideas on the relation of a parasite’s cellular metabolism and of drug action, i.e. by 
providing a negative proof for the existence of chemoreceptors on the surfaces of parasite 
cells. This approach does also serve to explain why British and German researchers continued 
to study the phenomenon of induced resistance in microbes for decades —despite it being 
absent from clinical medicine. After all, there existed very few chemotherapies of infectious 
diseases prior to the arrival of the sulfa drugs. Moreover, resistance to such medicines was 
rarely observed. However, being part and parcel of Ehrlich’s theories, his views on resistance 
were also criticised together with these. It was in particular Henry Dale who would challenge 
Ehrlich’s views of resistance being an inheritable and stable trait of microbes. Instead he in-
sisted that understanding this «wholly mysterious phenomenon» required taking into account 
some host interaction. Induced resistance, which had come into being as a chance discovery 
on the chemotherapy of sleeping sickness, thus became one of the more important laboratory 
models of twentieth-century immunological research. Its early history is largely discontinuous 
with later work, and antimicrobial resistance as it evolved from 1900 to 1940 followed other 
trajectories than those which became relevant after 1940.
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1. Histories of antibiotic resistance
Few historical phenomena seem so closely linked as the histories of twentieth-
century anti-infective chemotherapy and the history of antibiotic resistance. 
Recent histories of sulfa drugs and antibiotics have left no doubt that the 
arrival of such medicines from the mid 1930s on was followed quickly 
by that of resistant strains of the microbes targeted by such medicines 1. 
Yet, the history of this phenomenon had other dimensions and we should 
be cautious of associating it only with histories of pharmacology, clinical 
medicine and public health. An important but neglected example is the 
place of antibiotic resistance in the history of bacterial genetics from the 
1930s, which pre-dates its occurrence in clinical medicine 2. In this paper I 
use the term «antibiotic resistance» in its widest sense to include synthetic 
chemicals, like arsenical and the sulfa drugs, as well as naturally occurring 
substances, such as penicillin and streptomycin. I argue that before the 
1940s, resistance for most physicians meant bodily resistance, e.g. the 
organism’s capacity to withstand an infection. Germany’s leading handbo-
ok of infectious diseases would, in 1930, define the term in that way. In 
relation to drug-induced, inheritable traits of microbes, the author, himself 
being an adherent of Paul Ehrlich’s immunology, would speak of secondary 
resistance 3. Others would use Ehrlich’s original term «Festigkeit» 4 or its 
 1. On antibiotics: Bud, Robert. Penicillin: triumph and tragedy. Oxford: Oxford University Press; 2007; 
Lesch, John E. The first miracle drugs: how the sulfa drugs transformed medicine. Oxford: 
Oxford University Press; 2007. On resistance: Summers, William C. Microbial drug resistance: 
a historical perspective. In: Wax, Richard G.; Lewis, Kim; Salyers, Abigail A.; Taber, Harry, eds. 
Bacterial resistance to antimicrobials. Boca Raton: CRC Press; 2008, p. 1-9; Straand, Jørund; 
Gradmann, Christoph; Lindbæk, Morton; Simonsen, Gunnar Skov. Antibiotic development 
and resistance. In: Heggenhougen, Kris; Quah, Stella, eds. International encyclopaedia of 
public health. San Diego: Academic Press; 2008, p. 200-211.
 2. Brock, Thomas D. The emergence of bacterial genetics. Cold Spring Harbour: Cold Spring 
Harbour Laboratory Press; 1990; Creager, Angela N. H. Adaption or selection? Old issues and 
new stakes in the postwar debates over bacterial drug resistance. Studies in History and 
Philosophy of Biological and Biomedical Sciences. 2007; 38: 159-190.
 3. Schlossberger, Hans. Chemotherapie der Infektionskrankheiten. In: Kolle, Wilhelm; Kraus, Rudolf; 
Uhlenhuth, Paul, eds. Handbuch der pathogenen Mikroorganismen. Jena-Berlin-Wien: Gustav 
Fischer-Urban und Schwarzenberg; 1930, p. 551-730.
 4. Fischl, Viktor; Fischl, Lili. Arzneifestigkeit, Avidität, Interferenz. Zeitschrift für Immunitätsforschung 
und experimentelle Therapie. 1934; 83: 324-335.
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English translation as fastness or drug resistance 5. Experimental medicine 
would not use the term to describe a trait of a microbe before the 1930s 6. 
It was only in specialised immunology, pharmacology and genetics that the 
term appeared in this meaning with some regularity.
Thus, antibiotic resistance, though only known to a few, was not a new 
concept in the 1940s. A literature review published in 1944 holds a few 
surprises 7. While the authors did consider questions that we would expect 
to be discussed, for example, whether resistance to chemicals as a trait of 
microbial species results from mutation or selection, they did not do so with 
respect to bacterial species we would expect to be addressed by clinicians 
or geneticists like Staphylococcus aureus or Escherichia coli 8. Instead the 
review deals almost exclusively with a certain genus of unicellular parasites, 
trypanosomes, some of which are known as the pathogen of human trypa-
nosomiasis. In relation to the various species of trypanosomes —and this is 
the real surprise— the authors point to some 40 years of research and a long 
list of resistances to various chemicals that could be artificially induced in 
these organisms. On top of this, the authors do not mention that this work 
had any clinical relevance in relation to the many trypanosomiases of men 
and animals, such as sleeping sickness, Chagas disease or Ngana.
So why was antibiotic resistance studied? To answer this question, I 
will reconstruct the historical situation in which drug resistance in trypa-
nosomes was first observed. I will then follow the development of what 
seems to have been a sustained interest for decades and finally ask how this 
research contributed to the more familiar debates about resistance as they 
 5. Browning, C. H.; Gulbransen, R. The treatment of relapses in experimental trypanosome infec-
tions: cures after repeated relapses without increasing the dose of the chemotherapeutic 
agent. Journal of Pathology and Bacteriology. 1928; 31 (1): 134-136. 
 6. If we take the Journal of Bacteriology as an example, the term resistance is fully absent in the 
1920s, in the 1930s it would appear in two different meanings related to either bodily or bac-
terial resistance. Only from the 1940s would it be exclusively employed to describe a trait of 
a microbe. Moberg, Carol L. Launching the antibiotic era. Personal accounts of the discovery 
and use of the first antibiotics. New York: The Rockefeller University Press; 1990, p. 563.
 7. Eagle, Harry; Magnuson, Harold J. The spontaneous development of arsenic-resistance in 
Trypanosoma equiperdum, and its mechanism. Pharmacology and Experimental Therapeutics. 
1944; 82 (2): 137-151.
 8. An introduction in: Summers, n. 1. Clinical researchers in those days would e.g. focus on gono-
cocci where resistance had been resulting from therapy with sulphonamides (Lesch, n. 1, p. 
277). Fleming and Florey would observe it for example in staphylococci when working with 
penicillin (Bud, n. 1). Bacterial geneticists would try to build laboratory models of mutation 
with bacteria such as Escherichia coli (Creager, n. 2).
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evolved from the 1940s. All this will be based on the guiding hypothesis 
that antimicrobial resistance as it evolved from 1900 to 1940 followed other 
trajectories than those which became relevant later on.
2. A therapy with side effects
There are good reasons to place the beginning of our story in the year 
1905, when at the Liverpool School of Tropical Hygiene two researchers, 
Anton Breinel and Harold Wolferstan Thomas, observed that the arsenical 
compound Atoxyl was capable of controlling the growth of trypanosomes 9. 
Atoxyl, an ostensibly non-toxic arsenical, had been synthesised in the 1880s 
and had so far enjoyed a somewhat inconspicuous career in the treatment 
of, for example, syphilitic disorders of the skin 10. Trypanosomes, which had 
been known for a few years had only two years earlier been identified as the 
pathogens of sleeping sickness 11. Following that there had been a rush to 
explore possibilities for their control and the two Liverpool researchers had 
observed that the parasites were vulnerable to the substance 12. From then 
on the drug followed two interconnected trajectories. The first of these is 
not so interesting for us. It was a short lived euphoria connected to Atoxyl 
as a remedy for sleeping sickness. From 1906 on it was tested on several 
expeditions in Africa. Yet Atoxyl did not fully live up to the therapeutic 
expectations: What it brought about was a slowing down of the progression 
 9. Thomas, H. Wolferstan. Some experiments in the treatment of trypanosomiasis. British Medical 
Journal. 1905; 2317: 1140-1143. Dale, Henry H. Chemotherapy. Physiological Reviews. 1925; 
3 (3): 359-393, here p. 373
 10. On Atoxyl: Riethmiller, Steven. Ehrlich, Bertheim, and Atoxyl. Bulletin of the History of Chemistry. 
1999; 23: 28-33.
 11. Lyons, Maryinez. African Trypanosomiasis. In: Kiple, Kenneth F., ed. The Cambridge world history 
of human disease. Cambridge: Cambridge University Press; 1993, p. 552-561. David Bruce has 
been credited with that discovery, but not without dispute: Boyd, John. Sleeping sickness: 
the Castellani-Bruce controversy. Notes and Records of the Royal Society of London. 1973; 
28: 93-110
 12. There had been predecessors starting with arsenical acid in 1899, but they were either less 
effective or too toxic (or both) (Dale, n. 9, p. 373). Pearce, Louise; Brown, Wade H. Experi-
mental trypanosomiasis: its application in chemotherapeutic investigations. The Journal of 
Experimental Medicine. 1918; 28: 109-147 for an overview of substances used in experimental 
research on trypanosomes.
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of an otherwise still 100% lethal disease 13. On top came violent side-effects. 
For lack of alternatives and a few other reasons it enjoyed a certain popula-
rity, but around the First World War it was pushed aside by more effective 
medicines, most notably Bayer 205, which became known as Germanin 14.
The second trajectory started in one of the institutions where atoxyl 
was studied, Paul Ehrlich’s Institute for Experimental Therapy in Frankfurt. 
Yet, here the perspective was different from what researchers in Africa 
focussed on. Whereas, for example, Robert Koch more or less restricted 
himself to therapeutic testing of atoxyl on the shores of Lake Victoria 15, 
Ehrlich pursued a research project in which fundamental immunology 
and therapy were intimately connected. To understand how research on 
resistance became part and parcel of such a research program it is useful 
to remind ourselves of the essential steps of its development. Ehrlich had 
focussed his early work on histological staining. For that purpose he had 
employed certain synthetic dyestuffs, known as aniline dyes. Such dyes 
had two peculiar properties that influenced their further career. First, they 
were synthetic chemicals and well defined standardised industrial products, 
implying that anything that was done by their application seemed easily 
reproducible. Secondly, they had specific affinities for (prokaryotic) bacterial 
cells, while leaving (eukaryotic) bodily cells unstained. In his dissertation of 
1885 Ehrlich had put forward an explanation of such staining that took it to 
be a physiological rather than a physical process. The event of staining was 
thus assumed to be bound up with a metabolic intake of colours by a given 
cell 16. It was but a small step to research the pharmacological qualities of 
such phenomena: in 1891 Ehrlich described the application of methylene 
blue for the staining of the pathogen of malaria, Plasmodium falciparum 
and subsequently tried it as a possible therapy on malarial patients.
 13. Scheube, B. Die Krankheiten der warmen Länder. Ein Handbuch für Ärzte. 3 ed. Jena: Gustav 
Fischer; 1910 (1896). A curative effect was possible for very early stages that were hard to 
diagnose, however.
 14. Eckart, Wolfgang U. Medizin und Kolonialimperialismus in Deutschland 1884-1945. Paderborn: 
Schöningh; 1997, p. 505-13. Tropenabteilung, Bayer Leverkusen. Die Chemotherapie der 
Schlafkrankheit. Leverkusen: Bayer; 1938. Lyons, Maryinez. The colonial disease: a social history 
of sleeping sickness in northern Zaire, 1900-1940. Cambridge: Cambridge University Press; 
1992.
 15. Gradmann, Christoph. Laboratory disease: Robert Koch’s medical bacteriology. Baltimore: Johns 
Hopkins Universiy Press; 2009: 213-225.
 16. Ehrlich, Paul. Das Sauerstoffbedürfnis des Organismus. Eine farbenanalytische Studie. Diss. Med. 
Medical Faculty, Friederich-Wilhelms-Universität zu Berlin; 1885.
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It was about ten years later, while developing his side-chain theory of 
immunity, when Ehrlich ventured into making more systematic statements 
on antibiotic chemotherapy 17. He proposed that relations between thera-
peutic molecules and microbes actually resembled those between toxins 
and antitoxins respectively: So-called chemoreceptors on the surface of 
microbial cells would facilitate the intake of therapeutic molecules, which 
would then eventually have an effect on these cells 18. The main advantage 
of such a therapy lay, so he stated, in its specificity. Ideally, just as infectious 
diseases were caused by single bacterial species, these would in turn be 
susceptible to medicines that would selectively target those cells. In 1906, 
Ehrlich famously made his claim about the possibility of «magic bullets» 
that killed germs but not host cells.
«If we picture an organism as infected by a certain species of bacterium, 
it will obviously be easy to effect a cure if substances have been discovered 
which have an exclusive affinity for these bacteria and act deleteriously or 
lethally on these alone, while at the same time they possess no affinity for 
the normal constituents of the body and can therefore have the least harmful, 
or other, effect on that body. Such substances would then be able to exert 
their full action exclusively on the parasite harboured within the organism 
and would represent, so to speak, magic bullets, which seek their target of 
their own accord» 19.
His thinking here can usefully be understood as a «theory of drug 
action», analogous to his side chain theory of immunity.
It was from 1904 that Ehrlich directed his work towards the development 
of such therapies. His choice of experimental object may seem strange, since 
he chose the parasitic pathogens of vector-borne tropical infections, trypa-
nosomiases in particular. Yet these unicellular parasites suited his interests 
rather well. First of all, two French researchers, Laveran and Mesnil, had 
 17. For introductions see Prüll, Cay-Rüdiger; Maehle, Andreas-Holger; Halliwell, Robert Francis. A 
short history of the drug receptor concept. Houndsmills, Basingstoke: Palgrave; 2009, p. 16-
40; Silverstein, Arthur. Paul Ehrlich’s receptor immunology: the magnificent obsession. San 
Diego: Academic Press; 2003.
 18. Ehrlich’s relevant papers are in volume 3 of his collected papers, Ehrlich, Paul. Gesammelte 
Arbeiten. Zusammengestellt und herausgegeben von F. Himmelweit. 3 vols. Berlin-Göttingen-
Heidelberg: Springer; 1956-1957.
 19. Ehrlich, Paul. Address delivered at the Dedication of the Georg-Speyer-Haus. In: Himmelweit, 
Fred, ed. The collected papers of Paul Ehrlich. London: Pergamon Press; 1960 (1906), p. 53-63 
(59).
Magic bullets and moving targets
Dynamis 2011; 31 (2): 305-321
311
recently demonstrated that the blood of mice infected with animal trypano-
somiasis (Ngana) could be cleared of these by the injection of an arsenical 
that was known as Fosters solution 20. Thomas’ and Breinel’s discovery of the 
effect of Atoxyl on these parasites followed suit and thus there were good 
reasons to see trypanosomes as promising candidates to build a laboratory 
model of the chemotherapy of infectious disease. They responded well to 
toxic chemicals 21, they were easy to cultivate, and as unicellular organisms 
they offered bigger, more distinct cell-functions than bacteria.
Ehrlich tested a large number of chemicals and the first effective prepa-
ration he came up with was a red synthetic dye, which subsequently became 
known as trypan red 22. Even though this constituted a working animal model 
of therapy through its success with mice, it was only of theoretical value 
as it turned out that it was not effective against varieties of trypanosoma 
pathogenic to humans 23. Trypan red was suited to demonstrate the principle 
of specific chemotherapy, but was unlikely to have any practical relevance.
The second preparation that Ehrlich came up with was of a more 
traditional design. The arsenical atoxyl had been synthesised in the 1880s. 
As I have mentioned, Ehrlich had not even discovered its suitability to 
treat trypanosomiasis himself, yet he delivered a new chemical formula 
of the substance and working on this chemical took his research a large 
step forward 24. It was on 4 March 1907 that he delivered a paper in Berlin 
about his experimental studies on trypanosomes that had by then occupied 
him for almost three years. Together with Kiyoshi Shiga, he had succeeded 
in identifying a whole series of chemicals that were effective in animal 
experiments. By doing so, they had eventually come across a bewildering 
phenomenon: susceptibility to such preparations could eventually drop and 
even disappear altogether after their prolonged application. This kind of 
reduced susceptibility was obviously a property of the pathogen, since it 
 20. Pearce; Brown, n. 12, p. 110.
 21. Better than most bacteria: Ehrlich, Paul; Shiga, Kiyoshi. Farbentherapeutische Versuche bei 
Trypanosomenerkrankung. In: Himmelweit, Fred, ed. The collected papers of Paul Ehrlich. 
London: Pergamon Press; 1960 (1904), p. 24-37 (24).
 22. Ehrlich; Shiga, n. 21.
 23. On the testing of various anti-trypansomal preparations by Robert Koch in East Africa: Koch, 
Robert. Schlußbericht über die Tätigkeit der deutschen Expedition zur Erforschung der 
Schlafkrankheit. In: Schwalbe, Julius, ed. Gesammelte Werke von Robert Koch. Leipzig: Verlag 
von Georg Thieme; 1912 (1907), p. 534-546 (542). Gradmann, n. 15, p. 221.
 24. Riethmiller, n. 10.
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could be inherited over generations of the parasites and even transferred 
together with the manipulated microbes between different laboratory ani-
mals at will. The first observation of that sort had been made in relation 
to fuchsin, a red dye:
«There must have been produced a fuchsin-fast or «fuchsin-resistant» 
strain. I have chosen this expression because I found that such a resistance, 
once acquired, appears to remain unaltered […]» 25. 
Upon further investigation, it turned out that the phenomenon could 
be induced by a host of other chemicals. Ehrlich suspected that it would 
eventually occur with any chemical effective against trypanosomes:
«Judging from our experience this should be a general phenomenon. In the 
likely event that more trypan-hostile chemicals will be revealed, it is also very 
likely that it will be possible to produce strains that are resistant to these» 26.
3. The impact of resistance
By the time induced drug resistance was first observed, it was a laboratory 
event in the sense that it was not observed outside of this environment. 
The phenomenon as Ehrlich could produce it was, for example, not noted 
by Robert Koch in East Africa, when he treated a large number of patients 
on Lake Victoria 27. What appear to be irreconcilable observations can be 
explained by the rather different setups of experimental therapy in Frankfurt 
and East Africa. Resistance in Ehrlich’s laboratory had been the result of a 
carefully monitored therapy that evolved over months. Koch, however, had 
usually confined treatment to massive shots of the medicine administered 
over just a few days. His patients would usually run from his camp anyway 
as soon as they felt better; without follow ups there was little chance of 
observing the phenomenon. Curiously enough, however, Ehrlich’s and Koch’s 
ideas on the subject even clashed in a single event. In Koch’s institute in 
 25. Ehrlich, Paul. Chemotherapeutische Trypanosomenstudien. Berliner Klinische Wochenschrift. 
1907; 44: 233-236; 280-283; 310-314; 341-344; 349-50. Ehrlich’s collaborator Röhl had taken 
the resistant strain through 36 generations and observed no alteration in its qualities (p. 341).
 26. Ehrlich, n. 25, p. 314.
 27. Gradmann, n. 15, p. 213-225
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Berlin a laboratory servant had incidentally been infected with sleeping 
sickness in August 1906. With Koch away in East-Africa, his treatment 
was largely guided by Ehrlich’s proposals. An atoxyl treatment was tried 
and half a year later, parasites turned out to have been made resistant. 
After this unwelcome discovery, which actually occurred almost simulta-
neously with Ehrlich’s paper on chemotherapy being presented in Berlin 
in February 1907, the patient’s body became a laboratory tool for Ehrlich’s 
pharmacopeia of synthetic dyestuffs of which a number were tested on the 
patient subsequently. Koch however, after his return to Germany, when 
presented with the phenomenon, insisted that he had never encountered 
it. For him, doctors in Germany had simply been using an inappropriate 
scheme of therapy instead of following the one he had recommended in 
his letters from Lake Victoria. He concluded that there was no such thing 
as drug resistant trypanosomes and consistently resumed atoxyl therapy 
which, he claimed, cured the patient 28.
 28. Gradmann, n. 15, p. 155-166.
Figure 1. Medical records of B Schmidt with (translated) comment: «24.1.07. Blood smear taken 
upon re-entry to hospital. Trypanosome strain cultivated; resistant to atoxyl». Source: Robert Koch 
Institute, Berlin.
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Of course, resistance indicated the limitations of atoxyl as a therapy 
for sleeping sickness. Ehrlich was, however, also deeply intrigued by the 
phenomenon in its own right. Resistance had some peculiar qualities that 
made it possible to investigate what he called the «therapeutic biology of 
the parasite» 29. Once acquired, it was an inheritable trait. It was also exclu-
sively a trait of the parasite, since it could be transferred together with the 
latter at will between various individual animals and even species, including 
humans. It was also specific in the sense that it would be confined to one 
chemical substance or sometimes closely related groups of these. 
But what did this peculiar discovery actually mean for contemporary 
medicine? If we consider antibiotic resistance as a clinical phenomenon, 
which has to be taken into account in the treatment of individual patients, 
the relevance was close to nothing. Ehrlich’s interest in atoxyl as a medicine 
for trypanosomiasis ceased in 1907 and this can be attributed to the above 
mentioned limitations of this kind of medicine, but also to the instance that 
severe side effects of this medicine, such as loss of eyesight, had become 
public 30. In this situation, Ehrlich himself took his interest in antibiotic 
chemotherapy from sleeping sickness to syphilis and from trypanosomes 
to spirochetes. As is well known, this resulted in the development of Sal-
varsan, which was marketed from 1910 on 31. However, no such thing as a 
resistant strain of the Spirochaeta pallida to Salvarsan ever turned up 32. 
Moreover, in quite a contrast to what everybody expected, Salvarsan was 
not first of a series of effective chemotherapies that would target com-
mon infectious diseases other than syphilis. Instead this medicine and its 
modifications remained the only effective antibacterial chemotherapy for 
almost 30 years, that is, until the arrival of the first sulfa drugs in the mid 
1930s 33. Once it had been observed, resistance did not gain importance as 
a clinical phenomenon. Not even in relation to the parasitic vector-borne 
infection of sleeping sickness, which was after all one of the major public 
health issues in colonial Africa, did resistant trypanosomes continue to be 
of some relevance. The reason is that in the treatment of sleeping sickness 
 29. Ehrlich, n. 25, p. 313.
 30. Gradmann, n. 15, p. 219; Tropenabteilung, n. 14, p. 31-34.
 31. On the introduction of Salvarsan: Sauerteig, Lutz. Ethische Richtlinien, Patientenrechte und 
ärztliches Verhalten bei der Arzneimittelerprobung 1892-1931. Medizinhistorisches Journal. 
2000; 35: 303-334. 
 32. Tropenabteilung, n. 14, p. 63-71.
 33. Lesch, n. 1.
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atoxyl was soon pushed aside by Tryparsamid and right after the First World 
War by Bayer 205, better known as Germanin 34. Both of these proved to 
be potent medicines which also had the advantages of fewer side effects 
and not inducing resistance in the trypanosomes. Atoxyl, even though it 
continued to be used, was now an outdated, yet cheap therapy with known 
side-effects.
However, Ehrlich, after losing interest in the therapy for sleeping sick-
ness, continued his interest in the resistant trypanosomes. He returned to 
the issue in several papers around 1910 which discussed the questions of 
chemotherapy and immunity 35. At the same time the phenomenon became 
generally known and it was for instance reproduced in bacteria such as 
 pneumococci 36 and two researchers even wrote on laws of resistance 37. 
To understand the fascination in the phenomenon we need to examine 
more closely why Ehrlich was so intrigued by it. A paper delivered in 
1909 provides us with some insight: «The discovery of resistant strains 
and their inspection in detail turned out to be the most valuable means 
to study the truly intimate chemical structure of the parasite» 38. Ehrlich’s 
theory of drug action linked chemical compounds to those parasite cells 
with suitable chemoreceptors on their surface, in much the same way by 
which toxins linked to antitoxins. Yet, it was not an easy task to find any 
evidence for the existence of such sites, let alone to describe single recep-
tors in more detail 39. Antibiotic resistance, however, provided a means of 
doing precisely this. Antibiotic chemotherapies had been envisioned as an 
 34. Tropenabteilung, n. 14.
 35. Ehrlich, Paul. Über Partialfunktionen der Zelle. In: Himmelweit, Fred, ed. The collected papers of 
Paul Ehrlich. London: Pergamon Press; 1960 (1909), p. 171-182; Ehrlich, Paul; Gonder, Richard. 
Experimentelle Chemotherapie. In: Himmelweit, Fred, ed. The collected papers of Paul Ehrlich. 
London: Pergamon Press; 1960 (1914), p. 559-582.
 36. Marks, Lewis H. Über einen arsenfesten Bakterienstamm. Zeitschrift für Immunitätsfoschung. 
1910; 6: 293-298. In the Zeitschrift für Immunitätsforschung around 1910 several such papers 
by Constantin Levaditi from the Institut Pasteur are reviewed.
 37. Morgenroth, J.; Rosenthal, F. Experimentell-therapeutische Studien bei Trypanosomeninfektionen. 
III. Mitteilung. Arzneifestigkeit der Trypanosomen gegenüber Verbindungen der Hydrocupre-
inreihe. Zeitschrift für Hygiene und Infektionskrankheiten. 1912; 71: 501-535.
 38. Ehrlich, Paul. Über die neuesten Ergebnisse auf dem Gebiet der Trypansosomenforschung. In: 
Himmelweit, Fred, ed. The collected papers of Paul Ehrlich. London: Pergamon Press; 1960 
(1909), p. 195-212 (195).
 39. On Ehrlich’s side chain theory: Prüll, Cay-Rüdiger. Part of a scientific master plan? - Paul Ehrlich 
(1854-1915) and the origins of his receptor concept. Medical History. 2003; 47: 331-354, Prüll; 
Maehle; Halliwell, n. 17, p. 16-40; Silverstein, n. 17.
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application of immunology in the first place. Yet, for the time being the 
traffic was in the opposite direction, as resistance became instead a tool to 
study mechanisms of immune response and address questions about the 
structure of cells. From 1910 to 1914, after he had suspended his work on 
the chemotherapy of sleeping sickness, Ehrlich published a whole series 
of papers on principal questions of chemotherapy, in all of which induc-
ing resistances is introduced as a handy analytical tool. In his Nobel Prize 
lecture «On Partial Functions of the Cell», he came back to the issue and 
described induced resistance as the best means of substantiating his claim 
that specific receptors existed on the surface of cells 40. The host of resist-
ances that could be produced in trypanosomes made them the ideal model 
organism for studying the therapeutic biology of the cell.
The evidence that could be produced this way was manifold: on a very 
basic level, resistance supplied evidence to Ehrlich’s theory of drug action 
that required a physiological uptake of therapeutic molecules by cells. 
Such observations were also confirmed for bacteria 41. For example, given 
a certain quantum of medicine that was injected into a laboratory animal’s 
bloodstream, this would disappear from the bloodstream if a susceptible 
pathogen was present. If resistance of this pathogen did arise, this uptake 
would gradually be suspended in a plausible relation to the strength of 
resistance. Secondly, the phenomenon of so-called cross-resistances could 
be exploited. If, for instance, induced resistance to arsenicals as a side-
effect produced resistance to other, chemically unrelated, dyes that had 
not been applied, this led Ehrlich to the conclusion that a single receptor 
on the surface of the cell was susceptible to both of these substances. The 
arsenic-resistant strain had also consistently lost its ability to be stained by 
these dyes, an ability which, of course, it had possessed in its non-resistant 
form 42. Resistance offered positive evidence for the existence of a device, 
namely the chemo-receptor, whose existence had so far been more or less 
theoretical.
 40. Ehrlich, Paul. Über Partialfunktionen der Zelle. In: Himmelweit, Fred, ed. The collected papers 
of Paul Ehrlich. London: Pergamon Press; 1960 (1909), p. 171-182 (178-179).
 41. Levaditi, Constantin; Twort, C. Su la trypanotoxine du bacillus subtilis. La toxo-résistance. Comptes 
rendus Soc. Biol. 1911; 70 (18): 799 did so in relation to bacterial toxins using Bacillus subtilis 
as an experimental model.
 42. Ehrlich, Paul. Über die neuesten Ergebnisse auf dem Gebiet der Trypansosomenforschung. In: 
Himmelweit, n. 35, 195-212 (209).
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4. A «wholly mysterious phenomenon»
Resistance had by the First World War become firmly connected to Ehrlich’s 
side chain theory of immunity and to his related views on chemotherapy. 
These, however, were not undisputed 43 and thus Ehrlich’s views on resistance 
were an attractive point of attack for those who wished to challenge his 
theories at large. The quality of evidence that resistance offered depended 
to a large extent on the stability of the phenomenon as being inheritable, 
transferable, quantifiable and specific. This, however, was doubted almost 
immediately. In 1908 Mesnil and Brimont from the Institut Pasteur showed 
that the stability and degree of resistances did vary when the parasites were 
transferred between species. Resistance produced in mice could disappear 
in rats, but «re-emerged» if the parasites were re-transferred to mice 44. 
While the stability of the phenomenon was reasserted in Ehrlich’s group, 
it was through such work that the specificity now seemed less impressive. 
Of course, cross-resistances had been noted from the outset, but were 
considered to be rare. Yet, as Gonder and Kudicke noted in 1912, there 
were now many cases where resistance to one chemical led to the same 
phenomenon arising in connection with other unrelated chemicals 45. Finally, 
the question of whether resistance arose from mutation and selection or 
adaption was open. While Ehrlich had opted for the first, he showed little 
interest in the issue as such; others, such as Constantin Levaditi, insisted 
that the issue was open and relevant 46.
Also it was unfortunate, and frequently pointed to, that there was in 
fact no action at all of arsenicals such as atoxyl on trypanosomes in vitro: 
an effect, however, which only took place in vivo was in any likelihood de-
pendant on some host interaction. The nature of this was unknown and also 
poorly accounted for in Ehrlich’s theory of chemotherapy, which centred on 
the interaction of parasite and drug 47. It was from such observations that 
Henry Dale launched his fundamental critique of Ehrlich’s chemotherapeutic 
 43. From the recent work by Prüll; Maehle; Halliwell, n. 17, p. 64-92 the impression can be gained 
that Ehrlich’s view on immunity was a minority opinion in the interwar years.
 44. This was demonstrated by Mesnil and Brimont in 1908, Dale, n. 9, p. 380.
 45. Reported in Dale, n. 9, p. 381.
 46. Levaditi; Twort, n. 41, reported in Zeitschrift für Immunitätsforschung. 1911: 419, 471.  Pring-
sheim, E. Zeitschrift für Immunitätsforschung. 1912, 287-288.
 47. The argument was put forward by Voegtlin and Smith. Dale, n. 9, p. 376.
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theories in 1923 48. Deconstructing resistance was an important part of 
it. The phenomenon, he conceded, did indeed stand out as evidence for 
Ehrlich’s statements such as on specific affinities of chemicals to parasite 
cells and of the existence of chemoreceptors. However, substantial evidence 
suggested that things were ultimately more complicated. Transferability of 
resistance was not a general rule and cross resistances to chemically non-
aligned substances were so widespread that Ehrlich’s explanation was insuffi-
cient. Dale also stressed that the whole model of chemotherapy demanded 
an immediate interaction of drugs and parasite cells, which was far from 
proven in a model that worked only in vivo in important examples, such 
as atoxyl. All in all, while not doubting the existence of drug resistance as 
such, Dale turned it from a cornerstone of Ehrlich’s theory into a «wholly 
mysterious phenomenon» 49.
5. A revival
One might expect that in the mid-1920s, ten years after Ehrlich’s death 
and after having been subject to major challenges, resistant trypanosomes 
would cease to be important as laboratory models and would be relegated 
to the status of a curious phenomenon arising in strange parasites treated 
in strange ways. Yet, apart from Dale’s critique, there were other factors 
lending stability. Beyond the standing of its followers, in German science 50 
it came to be of importance that the program had been developed in co-
operation with the pharmaceutical industry. The best documented case is 
the cooperation of the Bayer Company and Ehrlich’s institute, where one 
of his assistants, Wilhelm Roehl, became head of the research department 
in 1911. In the following decades Bayer had a long-term involvement in 
synthetic remedies for tropical diseases, such as malaria and sleeping sick-
ness. None of these produced resistance, but at Bayer no one doubted the 
phenomena itself: Roehl in the early 1920s stated his allegiance to Ehrlich’s 
theory and reaffirmed that the phenomenon of resistance offered an outs-
 48. Dale, n. 9.
 49. Dale, n. 9, p. 381.
 50. Fischl; Fischl, n. 4; Schlossberger, n. 3.
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tanding way to understand drug action – even if it did not have immediate 
practical relevance 51.
Still it was from quite another angle that studies in drug resistance and 
the trypanosome model for their investigation was revitalised. From 1931 
onwards, a group of researchers at the Liverpool School of Tropical Hygiene 
began to investigate the experimental treatment of trypanosomiasis and 
resistances in great detail. Their strategy was two-fold. Firstly, to reaffirm 
the central observations that Ehrlich had built upon (quantifiability, trans-
ferability, stability and hereditary character) and, secondly, to investigate 
the «weak spot», that is, to investigate more closely the stages in which 
the medicines were metabolised by parasite and host 52. The group’s work 
started with trypanosomes, but was gradually expanded to other parasites 
such as spirochetes. In the papers of Frank Hawkings, Frederick Murgatroyd 
and Warrington Yorke the sphere of interest was still very much experi-
mental chemotherapy. It is surprising to see that there are no connections 
whatsoever of their work to the emerging field of bacterial genetics where 
antibiotic resistance was also exploited. What is important to see is that 
both approaches not only differed in focus, but also in the experimental 
models employed. While geneticists were investigating whether resistance 
in bacteria, such as Escherichia coli, resulted from mutation or selection 
within a bacterial culture, such questions were absent in the work of the 
Liverpool researchers who continued to employ the trypanosome model-
system 53. At the same time, the argument was put forward by the director 
of the trypanosome research centre in Entebbe/Uganda, Herbert Charles 
 51. In 1926 he delivered an address to the 6th Annual meeting of the Deutsche Pharmakologische 
Gesellschaft on «Theoretische Grundlagen der Chemotherapie» [theoretical foundations of 
chemo therapy], where he explicitly referred to Ehrlich’s theory as a frame for Bayer’s work 
on drug development. (Bayer archive/Leverkusen).
 52. Yorke, Warrington; Murgatroyd, Frederick; Hawking, Frank. Studies in chemotherapy: V. Preliminary 
contribution on the nature of drug resistance. Annals of Tropical Medicine and Parasitology. 
1931; 25: 351-358. This was followed by a whole series of papers in the following years, 
which were published in the Annals of Tropical Medicine down to 1938. Much of it was based 
on Frank Hawking’s work, who in 1933 had delivered a thesis on induced drug resistance 
in trypanosome. Power, Helen J. Tropical medicine in the twentieth century: a history of 
the Liverpool School of Tropical Medicine 1898-1990. London and New York: Keagan Paul 
International; 1999: 90-93.
 53. Borman, Earle K. Comparative studies on the natural and acquired resistance of certain strains 
of Escherichia Coli to the bacteriostatic and germicidal effects of cations. Journal of Bacte-
riology. 1932; 23: 315-329.
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Lyndhurst-Duke, that trypanosome studies of this kind also had little if any 
relevance for clinical medicine. This was less motivated by the fact that there 
were enough medicines for sleeping sickness that did not induce resistance. 
What seems more important is that the Liverpool group had specialised 
in other varieties of parasite, T. rhodesiense and T. equiperdum rather than 
T. gambiense which causes sleeping sickness. Since, however, Atoxyl was 
still employed to some extent for various reasons, this was unfortunate. As 
Lyndhurst-Duke reminded his readers, it was far from clear whether drug 
resistance, as it was studied by the Liverpool group, could be equated with 
the phenomena that occurred in patients with sleeping sickness 54. 
This type of criticism pointed to a feature that was characteristic for 
research into the chemotherapy of infectious disease from 1900 to 1940, 
namely its increasingly distant relationship to clinical medicine. It is in 
this sense no coincidence that, as it had been mentioned at the outset, the 
term resistance, understood as a trait of a parasite, had not found its way 
into the language of contemporary clinical medicine. Resistance for most 
meant bodily resistance e.g. the capacity of an organism to withstand an 
infection. Even in experimental medicine, it was only from the 1930s that 
the term resistance came to be employed to describe a trait of a microbe. 
Until those days such a usage would be confined to specialised immunology, 
pharmacology and genetics.
6. Conclusions
The early history of antimicrobial resistance was that of a chance disco-
very, resistance in trypanosomes, which was developed into a laboratory 
model delivering evidence to support Ehrlich’s theory of chemotherapy. 
Trypanosomes had been popular in chemotherapeutic research before, yet 
resistance made them even more attractive, since there was no other known 
microbe in which such a multitude of resistances could be induced. Thus, 
an irritating phenomenon from the early days of chemotherapy became a 
laboratory model to study (parasite) cell functions in relation to immunity. 
That this exclusive status was diminished by the rise of bacterial genetics 
 54. Lyndhurst Duke, Herbert. The trypanosomes of man: their resistance to arsenical drugs. The 
Lancet. 1933: 553-557, Lyndhurst Duke, Herbert. Arsenic resistance in trypanosmomes, Letter 
to the editor. The Lancet. 1935: 903-904.
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and by the arrival of sulfas and fungal antibiotics points to another reason 
for it being popular for 30 years: the fact that Ehrlich’s chemotherapy pro-
gram had not resulted in a long line of such medicines and that even in the 
case of those that existed, their effect could not be explained sufficiently. 
Even his former collaborator Browning commented in 1935 that Ehrlich’s 
grand scheme had resulted in nothing but «four distinct malarials —six 
groups of trypanocidal compounds— many new antiseptics and an almost 
miraculous spirochaeticide» 55. In the mid 1930s Ehrlich’s chemotherapy 
looked like a once promising child that had died in junior boots. In this 
sense it seemed to share the fate of Ehrlich’s side-chain theory of immunity 
to which it was closely linked. All in all, one should be careful not to inter-
pret the early history of antibacterial chemotherapy from the perspective 
of the post-1940 period when it became a success story. Perceived from 
within, it was rather a period of disillusionment. In the absence of working 
therapeutic molecules, the study of chemotherapy in general developed 
into an ivory tower inhabited by immunologists and pharmacologists, and 
resistant trypanosomes were among the most popular toys in that setting.
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